4 Med Tech and Drug Dividend Stocks to Buy With Huge 2017 Potential

One thing that many on Wall Street felt was hampering the pharmaceutical and medical technology stocks was the potential for a Hillary Clinton victory last month. Her harsh rhetoric on drug pricing cast a pall over both areas and they each have suffered badly. While Donald Trump’s victory would seem a positive for both, since November 8 the majority of the stocks in the Merrill Lynch med tech universe are down, and down big. We screened for the pharmaceutical and med tech companies that are Buy rated and pay the biggest dividends. With many stock investors looking for value, these could have big 2017 upside potential...

Shares of this top pharmaceutical stock with very solid growth potential are down over 15% from highs hit last summer. Abbott Laboratories (NYSE: ABT) is a leading diversified global health care company that develops, manufactures and markets branded generics, medical devices, nutritional products and diagnostic solutions. This is another stock with substantial upside potential. Eli Lilly and Co. (NYSE: LLY) is a global health care company with numerous core products in a number of primary-care pharmaceutical markets. The company generates revenues from its pharmaceutical product and animal health segments. This stock is down a sharp 15% in less than a month. Medtronic PLC (NYSE: MDT) is a medical devices giant, and many on Wall Street saw its historical merger with Covidien, probably one of the largest in the med tech industry, as a momentous event, leading to the creation of a unique company that combines the extensive and innovative abilities of both companies.

Source: Wall St 24/7

Related Articles:
- 4 Communications Services Stocks With Increasing Dividends
- 5 Stocks With Room To Grow Their Dividend
- 9 Dividend Stocks Ignoring The 4% Rule
- 10 Stocks That Have Paid Dividends For Over 100 Years
- Love People, Use Dividend Stocks